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ABSTRACT
Several studies have investigated the role played by killer immunoglobulin-like receptors (KIRs) and their
ligands on the outcome of hematopoietic stem cell transplantation (HSCT) in patients affected by
oncohematologic diseases. However, the interpretation of the results of these studies is considerably
hampered by the heterogeneity of the diseases, disease status at transplantation, and the different
protocols employed for both conditioning and graft-versus-host disease (GVHD) prophylaxis. To better
define the role of KIRs in HSCT, we studied KIR genotypes and HLA class I ligands in a homogeneous
group of 45 thalassemia patients transplanted with bone marrow cells from an HLA-identical, unrelated
donor. Patients that were heterozygotes for HLA-Cw groups 1 (HLA-CwAsn80) and 2 (HLA-CwLys80) had
a higher risk of developing acute GVHD than C1/C1 or C2/C2 homozygotes (relative risk [RR]  8.75;
95% confidence interval [CI]: 1.63-46.76; P  .007). Vice versa, all patients who experienced primary/
secondary graft failure were C1/C1 or C2/C2 homozygotes (RR  20.45; 95% CI  1.08-384.24; P  .009).
Moreover, the presence of the HLA-A11 antigen conferred protection against GVHD (0% versus 35%, P 
.02). Our results suggest that C1/C2 heterozygosity, may favor the development of donor alloreactivity and
thereby increase the risk of GVHD. Conversely, C1/C1 and C2/C2 homozygosity seems to reduce the risk
of GVHD but may increase the incidence of graft rejection. These data may be helpful in tailoring the
intensity of GVHD prophylaxis and conditioning regimens in thalassemia patients receiving HSCT from
an HLA-identical volunteer donor.
© 2007 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
The family of killer immunoglobulin-like recep-
or (KIR) genes currently consists of 15 functional
enes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4,
IR2DL5A,KIR2DL5B,KIR2DS1,KIR2DS2,KIR2DS3,
IR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, a
358IR3DS1) and 2 pseudogenes (KIR2DP1 and KIR3DP1)
ncoded within a 100-200-kb region of the Leukocyte
eceptor Complex (LRC) on chromosome 19q13.4
1]. KIR genes are organized within the LRC as haplo-
ypes, which have been shown to exhibit extensive vari-
tion in the number and type of KIR genes present [2].
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Role of KIR Ligands in UD-BMT for Thalassemia 1359The receptors encoded by these genes are a cluster
f polymorphic immunoglobulin-like molecules that
odulate the cytotoxic activity of natural killer (NK)
ells through interaction with HLA class I classical
nd nonclassical molecules [3].
HLA-Cw is the predominant ligand for the
DL1, 2DL2, and 2DL3 inhibitory KIRs and the
DS1 and 2DS2 activatory KIRs [4]. The replace-
ent of an amino acid residue at positions 77 and 80
f the HLA-C -helix makes it possible to divide
LA-Cw molecules into 2 groups, C1 (HLA-
wAsn80) and C2 (HLA-CwLys80), each 1 selectively
ecognized by a speciﬁc pair of activatory/inhibitory
IRs [5-10]. The molecules belonging to the HLA-
w4 group present epitopes recognized by the
DL1 inhibitory KIR, whereas HLA-A3 and HLA-
11 molecules present epitopes recognized by the
DL2 inhibitory KIR [11-15]. HLA-G Class I mol-
cules have been reported to inhibit NK cytotoxic-
ty at the maternal-fetal interface by binding with
he 2DL4 inhibitory KIR, and could play an impor-
ant role in the development/maintenance of mater-
al-fetal tolerance [16,17]. Despite the recent in-
ights into KIR-ligand interactions, not all KIR
igands are known, particularly those involving ac-
ivatory KIRs.
In T cell-depleted allogeneic hematopoietic
tem cell transplantation (HSCT) from an HLA-
aploidentical family donor, it has been demon-
trated that donor NK alloreactive cells exert a
raft-versus-leukemia effect, which reduces the risk
or relapse of myeloid leukemia, and confer protec-
ion against graft-versus-host disease (GVHD) and
ejection through lysis of recipient antigen-present-
ng cells and T lymphocytes, respectively [18-20].
umerous studies have investigated the inﬂuence of
IRs on the outcome of unmanipulated related and
nrelated HSCT for hematological malignancies,
ut the results remain controversial [21-25]. Dis-
ase heterogeneity, disease status at transplantation,
s well as differences in conditioning regimens and
VHD prophylaxis, may at least partly explain the
iscrepancies in the results of these studies. Thalas-
emia patients undergoing HSCT have a competent
mmune system that has not been compromised by
revious chemotherapy and constitute a homoge-
eous cohort in terms of disease, stem cell source,
onditioning regimen, and GVHD prophylaxis. For
his reason HLA-identical unrelated HSCT for
halassemia represents an ideal model for the eval-
ation of the role of immunogenetic factors in the
utcome of transplantation.
To further contribute to the comprehension of the
ole of KIR-ligand interactions in HSCT, we investi-
ated the KIR gene content and the currently known
LA class I ligands in a group of 45 thalassemiaatients transplanted in 3 Italian Bone Marrow Trans-
lantation (BMT) Centers.
ATIENTS AND METHODS
atients and Donors
KIR gene content was retrospectively evaluated in
5 -thalassemia major patients transplanted from an
nrelated donor from September 1993 to December
005. The study was approved by the local institu-
ional review board of each participating Center, and
nformed consent was obtained from all patients or
rom their parents or legal guardians. The clinical
haracteristics of donor-recipient pairs are reported in
able 1. Median time of follow-up for surviving pa-
ients was 4 years and 7 months (range: 1.5-14 years).
wenty patients were females (44%) and 25 males
56%), the age range being 2-26 years (median age
able 1. Clinical Data and Transplantation Outcome of 45
eta-Thalassemia Patients
o. of patients 45
edian patient age, years (range) 12.4 (2-26)
edian donor age, years (range) 33 (19-47)
atient/donor sex
Male patient with female
donor, n (%) 14 (31.1%)
Other combinations, n (%) 31 (68.9%)
isk class*
1, n (%) 14 (31.1%)
2, n (%) 18 (40%)
3, n (%) 13 (28.9%)
atient/donor CMV serology
Negative/negative, n (%) 5 (11.1%)
Other combinations, n (%) 40 (88.9%)
atient/donor HLA compatibility
Class I (-A, -B, -C) and II
(-DRB, -DQB1) match, n (%) 44 (97.8%)
Single Class I mismatch, n (%) 1 (2.2%)
HLA-DPB1 match or
permissive mismatch†, n (%) 27 (60%)
HLA-DPB1 nonpermissive
mismatch ¡ HVG†, n (%) 11 (24.4%)
HLA-DPB1 nonpermissive
mismatch ¡ GVH†, n (%) 7 (15.6%)
onditioning regimen
BU-TT-CY 28 (62.2%)
BU-TT-FLU 17 (37.8%)
edian cell dose, 108/kg (range) 4.5 (2-15)
ransplantation outcome
Rejection, n (%) 7 (15.6%)
aGvHD grade II-IV, n (%) 12 (31.5%)
Overall survival, n (%) 39 (86.7%)
Thalassemia-free survival, n (%) 32 (71.1%)
Transplantation-related
mortality, n (%) 6 (13.3%)
VG indicates host-versus-graft; GVH, graft-versus-host; CMV,
cytomegalovirus; BU, Busulfan; TT, Thiotepa; CY, Cyclophos-
phamide; FLU, Fludarabine.
Risk class according to the Pesaro classiﬁcation [26].
Classiﬁcation of HLA-DPB1 alleles was performed according to thealgorithm described by Zino et al [30] and Fleischhauer et al [31].
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G. La Nasa et al.13602.5). Twenty-two unrelated donors were female
48%) and 23 male (52%), age range being 19 to 47
ears (median 33 years). Fourteen male recipients
31%) had been transplanted from a female donor.
Prior to transplantation, the patients had been
ssigned to 1 of 3 risk classes according to the criteria
roposed by Lucarelli et al [26]. The patients had a
omogeneous distribution among the 3 risk classes: 14
ere assigned to Risk Class 1 (low risk), 18 to Risk
lass 2 (intermediate risk), and 13 to Risk Class 3
high risk).
ransplantation Regimen and GVHD Prophylaxis
All patients were prepared for the allograft using a
yeloablative conditioning regimen. In 30 cases the
onditioning regimen included Busulfan (BU), 3.5
g/kg by mouth daily in divided doses for 4 days (total
ose 14 mg/kg), Thiotepa (TT), 10 mg/kg i.v. admin-
stered in 2 doses on the same day, followed by Cy-
lophosphamide (CY), 50 mg/kg i.v. once daily for 4
ays (total dose 200 mg/kg) or CY 60 mg/kg i.v. once
aily for 2 days (total dose 120 mg/kg) depending
pon the risk class according to Lucarelli et al [26].
he remaining 15 patients were given a modiﬁed
onditioning regimen with BU14, TT10, and Flu-
arabine (FLU), 40 mg/m2 i.v. administered once
aily for 4 days (total dose 160 mg/m2) [27].
To prevent any risk related to persistent cyto-
enia in patients with poor graft function, an autol-
gous rescue of bone marrow cells was harvested
nd cryopreserved before transplantation for all pa-
ients. All patients received unmanipulated bone
arrow cells. Marrow was infused 48-72 hours after
he last dose of CY/FLU. All patients received
VHD prophylaxis with cyclosporine-A (Cs-A), 3
g/kg/day i.v. starting from day 2, and short-
erm methotrexate (MTX), 15 mg/m2 on day 1
nd 10 mg/m2 on days 3, 6, and 11. Cs-A was
witched to 6 mg/kg/day orally as soon as oral
dministration could be tolerated; starting from day
90, the dose was tapered, until discontinuation at
year. Engraftment was documented by in situ Y
hromosome hybridization of bone marrow or
lood samples in sex-mismatched donor/recipient
airs and by analysis of short tandem repeats on
lood and/or bone marrow samples in sex-matched
airs.
Acute GVHD (aGVHD) was graded according to
nternationally accepted criteria [28,29]. Graft rejec-
ion was deﬁned as either the absence of hematopoi-
tic reconstitution of donor origin on day 45 after
he allograft (primary graft rejection) or as loss of
onor cells after transient engraftment of donor-ori-
in hematopoiesis, with return to transfusion depen-
ence (secondary graft rejection). uLA Typing
All patients and donors were HLA typed using
igh-resolution molecular techniques. DNA for mo-
ecular typing was extracted from whole blood using
tandard methods. The alleles at the HLA-A, -B, -C,
DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1,
nd -DPB1 loci were identiﬁed by polymerase chain
eaction-sequence-speciﬁc primers (PCR-SSP) (Dy-
al, Oslo, Norway) and sequence-based typing.
Forty-four donor/recipient pairs were matched at
olecular level for the HLA-A, -B, -C, -DRB1, -DRB3,
DRB4, -DRB5, -DQA1, and -DQB1 loci. One donor/
ecipient pair had a disparity at the HLA-C locus
Cw*0501 versus Cw*0202), but both HLA-Cw mole-
ules belonged to the C2 ligand group (CwLys80). Twen-
y-seven patients (60%) were matched or permissively
ismatched with their donors for the HLA-DPB1 al-
eles, 11 (24%) had at least 1 nonpermissive DPB1 dis-
arity in host-versus-graft direction, and 7 (16%) had a
onpermissive DPB1 disparity in GVHD direction
30,31].
yping of KIR Genes
The KIR genes 2DL1, 2DL2, 2DL3, 2DL4,
DL5, 3DL1, 3DL2, 3DL3, 2DS1, 2DS2, 2DS3,
DS4, and 3DS1 were typed using the KIR-gene-
peciﬁc primers described by Uhrberg et al with mi-
or modiﬁcations [32]. The KIR gene 2DS5 was
yped using the primers described by Gagne et al [33].
tatistical Analysis
Patient, disease, and transplant-related variables
ere expressed as median and range or as percentage,
s appropriate. The following variables were analyzed
or their potential impact on outcome: donor and
ecipient sex, donor and recipient age, Pesaro risk
lass at HSCT, cytomegalovirus (CMV) serology,
onditioning regimen, marrow cell dose infused, HLA
lass I mismatch, HLA-DPB1 disparity, classiﬁed in 1
f 3 categories according to the identity, or degree of
ermissivity in case of disparity [30,31]. Patients were
ensored at the time of rejection, death, or last follow-
p. Probabilities of overall survival (OS) and survival
ith transfusion independence (thalassemia-free sur-
ival) were estimated by the Kaplan-Meier method
nd expressed as percentage with a 95% conﬁdence
nterval (CI) [34]. The probability of developing
GVHD, experiencing rejection or transplantation-
elated mortality (TRM) was expressed as cumulative
ncidence curves to adjust the analysis for competing
isks, namely death and graft failure for GVHD and
eath for graft failure [35,36]. The signiﬁcance of
ifferences between curves was estimated by the log-
ank test. Furthermore, the differences in percentages
f events in the groups of patients were compared
sing the 2-sided Fisher’s exact P test or a 2, as
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Role of KIR Ligands in UD-BMT for Thalassemia 1361ppropriate. P-values of .05 were considered as sig-
iﬁcant. Due to the limited size of the cohort ana-
yzed, no correction was made for multiple compari-
ons. Variables with a P-value .5 in univariate
nalysis were included in a multivariate analysis per-
ormed using the Cox proportional hazard regression
odel [37,38]. Statistical analysis was performed using
he SAS System (SAS, Cary, NC) and the NCSS
omputer program (J. Hintze, 2001, NCSS and PASS,
umber Cruncher Statistical System, Kaysville, UT).
ESULTS
linical Outcome
The results obtained in our patient cohort are
eported in Table 1. Figure 1 shows the 3-year
aplan-Meier estimates of survival (86.7%), thalasse-
ia-free survival (71.1%), the cumulative incidence of
ejection (15.6%), and TRM (13.3%) for the 45 pa-
ients studied. Twelve (31%) and 5 (13%) patients
eveloped grade II-IV and grade III-IV aGVHD, re-
pectively. Seven patients rejected the allograft and 6
ied of transplant-related complications: 4 patients
ied of aGVHD, 1 of liver failure secondary to
hronic GVHD (cGVHD), and 1 of CMV-related
nterstitial pneumonia.
IR Gene Frequencies
Comparisons of KIR gene frequencies among do-
ors, recipients, and a panel of healthy blood donors
id not yield signiﬁcant differences in the KIR gene
istribution. The gene frequencies were similar to
hose reported in other Caucasoid populations
igure 1. Kaplan-Meier probabilities of overall survival, thalasse-
ia-free survival and cumulative incidence of mortality and rejec-
ion in 45 thalassemia patients transplanted from an unrelated
onor.32,39]. Of the 14 KIR genes analyzed, the frameworkenes 2DL4, 3DL2, and 3DL3 were present in all
onor and recipient pairs and 2DL1 was present in 88
98%) of the 90 subjects examined. Most variations
ere observed for the number and speciﬁcity of acti-
atory KIR genes, particularly 2DS1, 2DS3, and
DS5, which were present in 47%, 31%, and 36% of
he total subjects, respectively. Interestingly, 5 of the 7
atients (71%) who rejected had 1-2 additional acti-
atory KIR genes compared to their donors (2DS2
nd 2DS3 in 1 case, 2DS1 in 2 cases, and 2DS3 in the
emaining 2 cases). There were no differences be-
ween the KIR gene proﬁle of patients that developed
rade II-IV aGVHD and their donors.
able 2. HLA Class I KIR Ligands and KIR Gene Proﬁles in 45
eta-Thalassemia Patients and Their Donors
o. of patients 45
atient KIR ligands
Patient C1/C1* 9 (20%)
Patient C2/C2* 14 (31.1%)
Patient C1/C2* 22 (48.9%)
Patient HLA-Bw4 present, n (%) 30 (66.6%)
Patient HLA-Bw4 absent, n (%) 15 (33.4%)
Patient HLA-A11 present, n (%) 11 (24.4%)
Patient HLA-A11 absent, n (%) 34 (75.6%)
onor/recipient KIR gene profile†
D < R, n (%) 13 (28.8%)
D > R, n (%) 16 (35.6%)
D  R, n (%) 16 (35.6%)
atient KIR ligand/donor activatory KIR‡
Patient-C1-absent/donor-KIR2DS2-
present, n (%) 9 (20%)
Other 3 combinations, n. (%) 36 (80%)
Patient-C2-absent/donor-KIR2DS1-
present, n (%) 3 (6.6%)
Other 3 combinations, n (%) 42 (93.4%)
atient KIR ligand/donor inhibitory KIR§
Patient-C1-absent/donor-KIR2DL2-
present, n (%) 9 (20%)
Other 3 combinations, n (%) 36 (80%)
Patient-C1-absent/donor-KIR2DL3-
present, n (%) 13 (28.8%)
Other 3 combinations, n (%) 32 (71.2%)
Patient-C2-absent/donor-KIR2DL1-
present, n (%) 9 (20%)
Other 3 combinations, n (%) 36 (80%)
Patient-Bw4-absent/donor 3DL1
present, n (%) 15 (35.7%)
Patient-Bw4-present/donor 3DL1
present, n (%) 27 (64.3%)
C1  HLA-CwAsn80 KIR ligand.
C2  HLA-CwLys80 KIR ligand.
Donor/recipient groups according to Gagne et al [33]: D  R 
donor KIR genotype included in the recipient KIR genotype;
D  R  recipient KIR genotype identical or included in the
donor KIR genotype; D  R  different KIR genotypes in the
donor and the recipient.
Combinations of donor 2DS2 and 2DS1 activatory KIRs and
patient C1 and C2 KIR ligands, according to the model pro-
posed by Cook et al [23].
Combinations of donor 2DL2, 2DL3, 2DL1, and 3DL1 inhibitory
KIRs with patient C1, C2, and Bw ligands, according to the
model proposed by Hsu et al [24].
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G. La Nasa et al.1362LA KIR Ligands and Their Influence on
ransplantation Outcome
The HLA-Cw KIR ligand was studied in the 45
onor/recipient pairs (Table 2): 20% (9 of 45) were
1/C1 homozygotes, 31% (14 of 45) were C2/C2
omozygotes, and 49% (22 of 45) were C1/C2 het-
rozygotes. The HLA-CwAsn80 and HLA-CwLys80
olecules expressed by donor/recipient pairs had a
igniﬁcant impact on transplantation outcome in our
ohort (Table 3). Univariate analysis showed that
hen donor/recipient pairs were C1/C2 heterozygotes,
atients had a higher risk of developing grade II-IV
GVHD (10 of 22; 45.5%) than patients of the C1/C1
r C2/C2 homozygous groups (2 of 23; 8.7%); RR 
.75; 95% CI  1.63-46.76; P  .007; log rank 
004; Figure 2). On the contrary, the 7 patients who
ejected the allograft were all C1/C1 or C2/C2 ho-
ozygotes (7 of 23; 30.4%) whereas none of the
1/C2 heterozygous patients experienced graft failure
0 of 22); RR  20.45; 95% CI  1.08-384.24; P 
009; log rank  .005; Figure 3). The increased risk of
GVHD observed in C1/C2 heterozygotes as well as
he increased risk of rejection observed in C1/C1 and
2/C2 homozygotes were conﬁrmed by multivariate
nalysis (RR 6.28 [95% CI  1.49-31.2], P  .01) and
RR 6.50 [95% CI  1.32-6.15], P  .05), respec-
ively. No signiﬁcant correlation was observed for OS,
nd thalassemia-free survival, even if the latter was
etter in the C1/C2 group (Figure 4).
HLA-Bw4 molecules are recognized by the
IR3DL1 receptor [14]. The frequency of KIR3DL1
as 93% in both donors and recipients. No signiﬁcant
ifferences were observed for the incidence of
GVHD or rejection related to the presence or ab-
ence of the HLA-Bw4 ligands in our donor/recipient
airs. In fact, in 30 HLA-Bw4 positive patients, the
ncidence of aGVHD was 27% (8 of 30) and the
ncidence of rejection was 13% (4 of 30), while in 15
LA-Bw4-negative patients the incidence of aGVHD
nd rejection was 27% (4 of 15) and 20% (3 of 15),
espectively (Tables 2 and 3).
HLA-A11 molecules present epitopes that are rec-
gnized by the 3DL2 inhibitory KIR framework gene
15]. Among the 45 donor/recipient pairs examined,
4% (11 of 45) expressed HLA-A11 molecules. None
f the patients expressing HLA-A11 molecules devel-
ped grade II-IV aGVHD (RR  0.08; 95% CI:
.004-1.44; P  .02; log rank  .03) (Figure 5 and
ables 2 and 3). The HLA-A11-positive patients were
venly distributed among the 3 groups of C1 or C2
omozygotes and C1/C2 heterozygotes (2 of 9, 6 of
4, and 3 of 22, respectively).
IR Genotype Analysis
Characterization of KIR genotypes made it possi-
le to subdivide the 45 donor/recipient pairs into 3 oroups according to 3 different combination patterns,
s described by Gagne et al [33] (Table 2). In 13 pairs
28%), the donor KIR genotype was included in the
ecipient KIR genotype [ie, the recipient had addi-
ional KIR genes absent in the corresponding donor
D  R)]. In 16 pairs (36%), the recipient KIR geno-
ype was either included or identical to the corre-
ponding donor KIR genotype (D  R). In the re-
aining 16 pairs (36%), the donor and the recipient
ad different KIR genotypes (D  R). The last group
as not considered for statistical analysis. The inci-
ence and grade of aGVHD were evaluated in the
bove-deﬁned groups of donors and recipients (Table 3).
hen the donor KIR genotype was included in the
ecipient KIR genotype (D  R), 31% (4 of 13) of
atients developed II-IV grade aGVHD compared to
5% (4 of 16) when the pair pattern was D  R (P 
s). The incidence of rejection was higher, although
ot statistically signiﬁcant, in the D  R group with 3
f 13 cases of rejection (23%), compared to 0 of 16
ases in the D  R group. No differences were ob-
erved between the 3 groups for OS, thalassemia-free
urvival, and TRM (Table 3).
nteraction between Donor KIRs and Recipient
LA Class I Ligands
We analyzed the 45 donor/recipient pairs to test
hether donor 2DS1 and 2DS2 activatory KIRs and
he presence or absence of C1 and C2 ligands in the
ecipients had an inﬂuence on the outcome of trans-
lantation [23]. We also investigated the effect of the
missing KIR ligand” for the inhibitory KIRs 2DL1,
DL2, 2DL3, and 3DL1 [24] (Tables 2 and 3).
In donor/recipient pairs with the combination pa-
ient-C1-absent/donor-KIR2DS2-present (9/45), the
ncidence of aGVHD was 11% (1/9) and the incidence
f rejection was 33% (3/9). In the patient-C1-present/
onor-KIR2DS2-present group (13 of 45), the inci-
ence of aGVHD was 31% (4 of 13) with no cases of
ejection. In donor/recipient pairs that were patient-
1-absent/donor-KIR2DS2-absent (5 of 45), we ob-
erved 1 case of aGVHD (20%) and a single case of
ejection (20%). In 18 of 45 pairs that were patient-
1-present/donor-KIR2DS2-absent, the incidence of
GVHD was 33% (6 of 18) and the incidence of
ejection was 17% (3 of 18). A comparison of the
atient-C1-absent/donor-KIR2DS2-present group with
hose of the other combinations did not yield signiﬁcant
ifferences for aGVHD or rejection. The analysis per-
ormed to evaluate if the presence of KIR2DS1 in the
onor had an inﬂuence on the outcome of patients lack-
ng the C2 ligands did not reveal any signiﬁcant associ-
tion (Table 3).
Analysis of donor 2DL1, 2DL2, 2DL3, and 3DL1
nhibitory KIRS showed that donors/recipients of the
1-absent/donor-KIR2DL2-present group (9 of 45)
nly had 1 case of aGVHD (11%) and 3 cases of rejec-
Table 3. Univariate Analysis for the Risk of aGVHD (Grade II-IV), Rejection, and Transplantation-Related Mortality and the Probability of Thalassemia-Free Survival in 45 Transplanted Thalassemia Patients
No. of Patients (%)
Total no. Patients Grade II-IV aGVHD Rejection
Thalassemia-Free
Survival
Transplantation-
Related Mortality
45 (100%) 12 (26.6%) P 7 (15.5%) P 32 (71.1%) P 6 (13.3%) P
Median patient age, years (range) 12.4 (2-26) 12.5 (4-23) .38 13 (3-15) ns 12 (2-26) ns 14.1 (9-19) .42
Median donor age, years (range) 33 (19-47) 34 (22-47) ns 36 (26-44) .21 34 (19-47) ns 30 (22-45) .43
Patient/donor sex ns .40 ns .35
Male patient with female donor, n (%) 14 (31.1%) 3 (25%) 1 (14.3%) 10 (31.2%) 3 (50%)
Other combinations, n (%) 31 (68.9%) 9 (75%) 6 (85.7%) 22 (68.8%) 3 (50%)
Risk Class* ns ns ns .33
1, n (%) 14 (31.1%) 4 (33.3%) 2 (28.6%) 11 (34.4%) 1 (16.7%)
2, n (%) 18 (40%) 5 (41.7%) 3 (42.8%) 13 (40.6%) 2 (33.3%)
3, n (%) 13 (28.9%) 3 (25%) 2 (28.6%) 8 (25%) 3 (50%)
Patient/donor CMV serology ns ns ns ns
Negative/negative, n (%) 5 (11.1%) 1 (8.3%) 0 (0%) 4 (12.5%) 1 (20%)
Other combinations, n (%) 40 (88.9%) 11 (91.7%) 7 (100%) 28 (87.5%) 5 (80%)
Patient/donor HLA compatibility
Class I (-A, -B, -C) and II (-DRB, -DQB1)
match, n (%) 44 (97.8%) 12 (100%) ns 7 (100%) ns 31 (96.9%) ns 6 (100%) ns
Single Class I mismatch, n (%) 1 (2.2%) 0 (0%) 0 (0%) 1 (3.1%) 0 (0%)
HLA-DPB1 match or permissive mismatch†,
n (%) 27 (60%) 6 (50%) ns 3 (42.8%) .41 22 (68.8%) .09 2 (33.3%) .19
HLA-DPB1 nonpermissive mismatch ¡ HVG†,
n (%) 11 (24.4%) 5 (41.7%) 3 (42.8%) 6 (18.6%) 2 (33.3%)
HLA-DPB1 nonpermissive mismatch ¡ GVH†,
n (%) 7 (15.6%) 1 (8.3%) 1 (14.4%) 4 (12.6%) 2 (33.3%)
Conditioning regimen ns ns .05 .02
BU-TT-CY 28 (62.2%) 6 (50%) 4 (57.2%) 14 (43.7%) 6 (100%)
BU-TT-FLU 17 (37.8%) 6 (50%) 3 (42.8%) 18 (56.3%) 0 (0%)
Median cell dose, 108/kg (range) 4.5 (2-15) 5.2 (2.7-9) ns 4.5 (2.6-7.5) .46 4.7 (2.1-15) .24 4.0 (3.4-7.5) .45
Patient KIR ligands
Patient C1/C1 or C2/C2 23 (51.1%) 2 (16.7%) .007 7 (100%) .009 14 (43.7%) .18 2 (33.3%) .41
Patient C1/C2 22 (48.9%) 10 (83.3%) 0 (0%) 18 (43.7%) 4 (66.7%)
Patient HLA-Bw4 present, n (%) 30 (66.6%) 8 (66.7%) ns 4 (57.2%) ns 22 (68.7%) ns 4 (66.7%) ns
Patient HLA-Bw4 absent, n (%) 15 (33.4%) 4 (33.3%) 3 (42.8%) 10 (31.3%) 2 (33.3%)
Patient HLA-A11 present, n (%) 11 (24.4%) 0 (0%) .02 2 (28.6%) ns 8 (25%) ns 1 (20%) ns
Patient HLA-A11 absent, n (%) 34 (75.6%) 12 (100%) 5 (71.4%) 24 (75%) 5 (80%)
Donor/recipient KIR gene profile‡ ns .08 .19 ns
D < R, n (%) 13 (28.8%) 4 (33.3%) 3 (42.8%) 8 (25%) 2 (33.3%)
D > R, n (%) 16 (35.6%) 4 (33.3%) 0 (0%) 14 (43.7%) 2 (33.3%)
D  R, n (%) 16 (35.6%) 4 (33.3%) ne 4 (57.2%) ne 10 (31.3%) ne 2 (33.3%) ne
Patient KIR ligand/donor activatory KIR§
Patient-C1-absent/donor-KIR2DS2-present, n (%) 9 (20%) 1 (8.3%) .40 3 (42.8%) .13 5 (15.6%) .41 1 (20%) ns
Other 3 combinations, n (%) 36 (80%) 11 (91.7%) 4 (57.2%) 27 (84.4%) 5 (80%)
Patient-C2-absent/donor-KIR2DS1-present, n (%) 3 (6.6%) 0 (0%) ns 0 (0%) ns 3 (9.4%) ns 0 (0%) ns
Other 3 combinations, n (%) 42 (93.4%) 12 (100%) 7 (100%) 29 (90.6%) 6 (100%)
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Table 3. (Continued)
No. of Patients (%)
Total no. Patie
Thalassemia-Free
Survival
Transplantation-
Related Mortality
45 (100%) 32 (71.1%) P 6 (13.3%) P
Patient KIR ligand/donor inhibitory KIR#
Patient-C1-absent/donor-KIR2DL2-present, n (%) 9 (20%) 5 (15.6%) .41 1 (20%) ns
Other 3 combinations, n (%) 36 (80%) 27 (84.4%) 5 (80%)
Patient-C1-absent/donor-KIR2DL3-present, n (%) 13 (28.8%) 8 (25%) .47 2 (33.3%) ns
Other 3 combinations, n (%) 32 (71.2%) 24 (75%) 4 (66.7%)
Patient-C2-absent/donor-KIR2DL1-present, n (%) 9 (20%) 6 (18.7%) ns 0 (0%) ns
Other 3 combinations, n (%) 36 (80%) 26 (81.3%) 6 (100%)
Patient-Bw4-absent/donor 3DL1 present, n (%) 15 (35.7%) 10 (34.5%) ns 2 (50%) ns
Patient-Bw4-present/donor 3DL1 present, n (%) 27 (64.3%) 19 (65.5%) 2 (50%)
CMV indicates cytomegalovirus; C1, HLA-CwAsn80 KIR ligand; C2, HLA-C t; BU, Busulfan; TT, Thiotepa; CY, Cyclophosphamide;
FLU, Fludarabine; ns, not signiﬁcant; ne, not evaluable; aGVHD, acute
*Risk Class according to the Pesaro classiﬁcation [26].
†Classiﬁcation of the HLA-DPB1 alleles was performed according to the a
‡Donor/recipient groups according to Gagne et al [33]: D  R  donor K cipient KIR genotype identical or included in the donor
KIR genotype; D  R  different KIR genotypes in the donor and the
§Combinations of donor 2DS2 and 2DS1 activatory KIRs and patient C1 a al [23].
#Combinations of donor 2DL2, 2DL3, 2DL1, and 3DL1 inhibitory KIRs osed by Hsu et al [24].
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graft-versus-host disease.
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Role of KIR Ligands in UD-BMT for Thalassemia 13653 of 9 versus 0 of 13; RR3.16; 95% CI 1.63-6.13;
 .054). No signiﬁcant differences were found in
omparisons between donor/recipient pairs of the pa-
ient-C1-absent/donor-KIR2DL3-present group (13/
5) and those of the other groups: patient-C1-absent/
onor-KIR2DL3-absent, patient-C1-present/donor-
IR2DL3-present, and patient-C1-present/donor-
IR2DL3-absent. The comparison between the
atient-C2-absent/donor-KIR2DL1-present group
9 of 45) and the other 3 groups (patient-C2-absent/
onor-KIR2DL1-absent, patient-C2-present/donor-
IR2DL1-present, and patient-C2-present/donor-
IR2DL1-absent), although not statistically signiﬁ-
ant, revealed a decreased risk for aGVHD (0 of 9
ersus 12 of 36) (RR  0.10; 95% CI  0-1.92; P 
086). No signiﬁcant differences were observed for the
ates of rejection.
Furthermore, no signiﬁcant differences were found
or aGVHD and rejection when the 15 pairs of the
atient-Bw4-absent/donor-KIR3DL1-present group were
ompared with the 27 pairs of the patient-Bw4-
resent/donor-KIR3DL1-present group (Table 3).
ISCUSSION
Unrelated donor BMT in thalassemia patients
epresents an ideal model for studying the impact of
mmunogenetic factors on transplantation outcome.
ifferent to patients with hematologic malignancies,
halassemia patients have comparable clinical charac-
eristics, a competent immune system, and receive
omogeneous conditioning regimens and GVHD
igure 4. Comparison of the probabilities of thalassemia-free sur-
ival (TFS) between 22 C1/C2 heterozygotes (events  18) and 23
1/C1 or C2/C2 homozygotes (C1/C1 patients  9, events 6;
2/C2 patients  14, events  8).rophylaxis. Moreover, the investigation of patho- hysiologic mechanisms implicated in GVHD, and
articularly rejection, is not hampered by the presence
f neoplastic cell clones and previous chemotherapy
reatment.
So far, only 1 report has analyzed the effect of
IR-KIR ligand interaction on the occurrence of
VHD and rejection in thalassemia [40]. That study
ncluded patients transplanted from an HLA identical
ibling, whereas the present study was performed on
he largest cohort of thalassemia patients transplanted
rom an unrelated donor.
The KIR gene frequencies observed in our donor/
ecipient pairs are similar to those previously reported
n other Caucasoid populations. No signiﬁcant differ-
nces in the KIR gene proﬁle were observed between
atients with aGVHD and their donors.
Incomplete elimination of recipient immunocom-
etent cells is a factor that plays a major role in
rimary or secondary graft failure, although the mech-
nisms underlying graft rejection remain to be com-
letely elucidated. It is now accepted that rejection of
onor hematopoietic cells is not only mediated by T
ell-speciﬁc immune response, but also by NK cells
41]. In our study, the patients who rejected the allo-
raft had 1 or 2 additional activatory KIRs compared
o their donors, even if the difference did not reach
tatistical signiﬁcance. When the donor/recipient
airs were stratiﬁed according to their KIR gene pro-
les as proposed by Gagne et al [33], there was a
endency toward rejection when the donor KIR geno-
ype was included in the recipient KIR genotype.
In previous studies, Ruggeri et al [9,18] showed
he impact of HLA-C differences as a cause of NK
lloreactivity and, more recently, Cook et al [23] dem-
igure 5. Impact of the presence of the HLA-A11 KIR antigen on
he incidence of grade II-IV aGVHD in 45 thalassemia patients
ransplanted from an unrelated donor. (HLA-A11 positive patients11, events  0; HLA-A11 negative patients  34, events 12).
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G. La Nasa et al.1366nstrated the inﬂuence of HLA-Cw KIR ligands as
isk factors, also in the absence of an HLA-mismatch
ith the donor. In fact, patients with myeloid disease
ransplanted from an HLA-identical sibling had a bet-
er outcome when donor and recipient pairs were
1/C2 heterozygotes or C1/C1 homozygotes. The
ame effect was not observed in transplants for lym-
hoid diseases. The same authors report a signiﬁcant
eduction of disease-free survival (DFS) when the do-
or carried the activatory KIR2DS2 gene and the recip-
ent lacked the respective C1 KIR ligand (patient-C1-
bsent/donor-KIR2DS2-present) in comparison with
ther combinations (patient-C1-present/donor-KIR2DS2-
resent and patient-C1-present/donor-KIR2DS2-ab-
ent). A similar analysis performed for KIR2DS1 and
he presence or absence of the KIR ligand C2 in the
ecipient did not reveal any additional effect for over-
ll survival or aGVHD. In our donor/recipient pairs,
nalysis of the 2DS1 and 2DS2 activatory KIRs and
heir ligands did not have any signiﬁcant effect on the
ncidence of aGVHD, rejection, OS, and/or thalasse-
ia-free survival (Tables 2 and 3).
Hsu et al [24] tested the “missing ligand hypoth-
sis” by investigating the effect of the presence/ab-
ence of HLA ligands for donor 2DL1, 2DL2, 2DL3,
nd 3DL1 inhibitory KIRs on the outcome of HLA
dentical sibling transplantation. They demonstrated
hat absence in the recipient of the HLA Class I ligand
or the 2DL1, 2DL2, 2DL3, and 3DL1 inhibitory
IRs was an independent predictive factor signiﬁ-
antly associated with a better transplantation out-
ome. In particular, patients lacking the HLA-Cw and
LA-Bw4 ligands for donor inhibitory KIRs dis-
layed a better DFS and OS than patients exhibiting
ll HLA class I ligands for donor inhibitory KIRs.
hen we applied the same algorithm to our patient
ampling, we observed a slight increase in the risk of
ejection in the C1-absent/donor-KIR2DL2-present
roup, compared to the C1-present/donor-KIR2DL2-
resent group. Analogously, when comparing the C2-ab-
ent/donor-KIR2DL1-present combination with those of
he other 3 groups (patient-C2-absent/donor-KIR2DL1-
bsent, patient-C2-present/donor-KIR2DL1-present
nd patient-C2-present/KIR2DL1-absent), we ob-
erved a lower risk for aGVHD, but again, the differ-
nce did not reach statistical signiﬁcance.
In our cohort of patients, the most signiﬁcant data
merge from the analysis of the HLA C1 and C2 KIR
igands. In fact, the probability of rejection was sig-
iﬁcantly higher (P  .009) when donor and recipient
airs were homozygotes for the ligands of the C1 and
2 groups (Figure 3). A possible explanation of this
nding is that the presence of a single subset of
LA-Cw ligands for activatory KIRs in C1 or C2
onor/recipient homozygotes could determine an in-
ufﬁciency of donor NK cell activation, thus preclud-
ng the complete eradication of recipient hematopoi-tic and immune cells. Conversely, it is not clear why
1/C2 heterozygotes had a signiﬁcantly increased risk
f experiencing GVHD (P  .007) (Figure 2). More-
ver, C1/C2 heterozygotes had a better, although not
tatistically signiﬁcant, thalassemia-free survival than
1/C1 or C2/C2 homozygotes (Figure 4).
The presence of the HLA-A11 antigen in donor/
ecipient pairs was associated with a protective effect
gainst GVHD (P  .02) (Figure 5 and Table 3). It
as been postulated that HLA-A11 and HLA-A3 an-
igens are ligands of KIR3DL2, although direct evi-
ence is lacking [42,43]. Indeed, it would seem that
ecognition of HLA-A3 and HLA-A11 by KIR3DL2
s strongly peptide-speciﬁc [15]. However, the func-
ional role of this interaction remains to be estab-
ished.
In conclusion, our data suggest that the status of
onor-recipient HLA class I ligands, and not the KIR
eceptor genotype, is predictive for the outcome of
nrelated donor HSCT in patients with -thalasse-
ia. Evaluation of the presence of HLA Class I li-
ands, particularly those of the C1 and C2 groups, and
he HLA-A11 antigen may facilitate the identiﬁcation
f patients at high risk of developing either aGVHD
r rejection, and thus help the clinician modulate the
ntensity of conditioning regimen and/or immunosup-
ressive therapy accordingly.
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